drugset / Trial / NCT03349008
Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B
RandomizedParallel-groupDouble-blindTreatment
Summary
This study evaluates the addition of glycyrrhizin to entecavir in the treatment of patients with chronic hepatitis B in China. Half of participants will receive magnesium isoglycyrrhizinate followed by oral diammonium glycyrrhizinate and entecavir in combination, while the other half will receive a placebo and entecavir.
Timeline
- Start
- 2017-11-25
- Primary completion
- 2019-12-31
- Completion
- 2020-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Diammonium glycyrrhizinate | Unknown | — | Oral |
| Subject | Magnesium Isoglycyrrhizinate | Unknown | — | Other |
| Background | Entecavir | Small molecule | — | — |